Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 13.02% | Add +0.7% | 570,000 | $76.21 | $43M | +4,000 | −$4M |
| STXS - Stereotaxis | 8.37% | Hold | 13,680,554 | $2.04 | $28M | — | — |
| Iveric Bio | 4.47% | Add +1.2% | 612,975 | $24.33 | $15M | +7,000 | +$2M |
| ASND - Ascendis Pharma A/S | 4.35% | Add +3.8% | 135,212 | $107.22 | $14M | +5,000 | −$1M |
| Karuna Therapeutics | 4.28% | Add +9.1% | 78,573 | $181.64 | $14M | +6,546 | +$119K |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.97% | Hold | 102,500 | $129.16 | $13M | — | — |
| RVMD - Revolution Medicines | 3.74% | Add +20.5% | 575,785 | $21.66 | $12M | +98,000 | +$1M |
| Blueprint Medicines | 3.52% | Hold | 261,235 | $44.99 | $12M | — | — |
| XENE - Xenon Pharmaceuticals | 3.39% | Hold | 316,092 | $35.79 | $11M | — | — |
| CYTK - Cytokinetics | 2.92% | Add +50.3% | 276,495 | $35.19 | $10M | +92,500 | +$1M |
| SNDX - Syndax Pharmaceuticals | 2.83% | Hold | 447,073 | $21.12 | $9M | — | — |
| DXCM - Dexcom | 2.35% | Hold | 67,552 | $116.18 | $8M | — | — |
| Sage Therapeutics | 2.27% | Hold | 180,306 | $41.96 | $8M | — | — |
| NBIX - Neurocrine Biosciences | 2.26% | Add +2.0% | 74,615 | $101.22 | $8M | +1,494 | −$1M |
| Morphic | 2.03% | Reduce −8.2% | 179,467 | $37.64 | $7M | −16,000 | +$2M |
| IDYA - Ideaya Biosciences | 1.93% | Hold | 468,358 | $13.73 | $6M | — | — |
| Cardiovascular Systems | 1.71% | Hold | 286,988 | $19.86 | $6M | — | — |
| Dice Therapeutics | 1.61% | Add +51.9% | 187,585 | $28.65 | $5M | +64,085 | +$2M |
| VKTX - Viking Therapeutics | 1.59% | Reduce −38.8% | 319,155 | $16.65 | $5M | −202,398 | +$411K |
| Merus | 1.57% | Add +5.2% | 283,998 | $18.40 | $5M | +14,105 | +$1M |
| ATRC - Atricure | 1.56% | Add +74.3% | 125,529 | $41.45 | $5M | +53,500 | +$2M |
| NRIX - Nurix Therapeutics | 1.51% | Hold | 566,695 | $8.88 | $5M | — | — |
| EWTX - Edgewise Therapeutics | 1.47% | Reduce −4.4% | 733,239 | $6.67 | $5M | −33,604 | −$2M |
| Kalvista Pharmaceuticals | 1.45% | Hold | 616,032 | $7.86 | $5M | — | — |
| BCRX - Biocryst Pharmaceuticals | 1.38% | Add +119.7% | 551,500 | $8.34 | $5M | +300,500 | +$2M |
| Adicet Bio | 1.38% | Add +26.2% | 797,054 | $5.76 | $5M | +165,500 | −$1M |
| IPSC - Century Therapeutics | 1.36% | Add +175.0% | 1,307,407 | $3.47 | $5M | +832,040 | +$2M |
| APLSUSD - Apellis Pharmaceuticals | 1.14% | Reduce −30.8% | 57,746 | $65.96 | $4M | −25,700 | −$506K |
| ALEC - Alector | 1.10% | Add +11.3% | 592,438 | $6.19 | $4M | +60,000 | −$1M |
| ARAY - Accuray | 1.09% | Hold | 1,222,358 | $2.97 | $4M | — | — |
| Mediwound | 1.03% | Add +26.2% | 257,653 | $13.32 | $3M | +53,571 | +$679K |
| BHVN - Biohaven | 0.96% | Reduce −40.1% | 235,613 | $13.66 | $3M | −157,500 | −$2M |
| RCUS - Arcus Biosciences | 0.96% | Add +23.2% | 175,217 | $18.24 | $3M | +33,000 | +$255K |
| AXGN - Axogen | 0.94% | Hold | 332,103 | $9.45 | $3M | — | — |
| Mirati Therapeutics | 0.82% | Hold | 73,600 | $37.18 | $3M | — | — |
| BCYC - Bicycle Therapeutics | 0.78% | Hold | 122,200 | $21.27 | $3M | — | — |
| AUTL - Autolus Therapeutics | 0.65% | Hold | 1,176,150 | $1.84 | $2M | — | — |
| Mersana Therapeutics | 0.63% | Add +23.6% | 510,863 | $4.11 | $2M | +97,400 | −$323K |
| LKFT - Galapagos | 0.61% | Hold | 52,675 | $38.64 | $2M | — | — |
| PRQR - Proqr Therapeutics | 0.60% | New | 940,582 | $2.13 | $2M | +940,582 | +$2M |
| Vigil Neuroscience | 0.51% | Add +2.1% | 172,308 | $9.79 | $2M | +3,462 | −$424K |
| KURA - Kura Oncology | 0.40% | Reduce −24.2% | 109,784 | $12.23 | $1M | −35,000 | −$454K |
| Iteos Therapeutics | 0.40% | Hold | 98,560 | $13.61 | $1M | — | — |
| Theseus Pharmaceuticals | 0.35% | Add +60.1% | 131,025 | $8.88 | $1M | +49,166 | +$756K |
| LRMR - Larimar Therapeutics | 0.32% | Reduce −49.9% | 236,873 | $4.53 | $1M | −236,263 | −$881K |
| ORIC - Oric Pharmaceuticals | 0.29% | Reduce −35.5% | 170,326 | $5.70 | $971K | −93,911 | −$585K |
| CATBUSD - Astria Therapeutics | 0.28% | New | 69,883 | $13.30 | $929K | +69,883 | +$929K |
| Neuronetics | 0.27% | Hold | 313,717 | $2.91 | $913K | — | — |
| BWAY - Brainsway | 0.25% | Add +115.4% | 473,981 | $1.76 | $832K | +253,981 | +$288K |
| Keros Therapeutics | 0.25% | Reduce −41.3% | 19,361 | $42.70 | $827K | −13,639 | −$758K |
| Genfit S A | 0.24% | Hold | 197,940 | $4.10 | $812K | — | — |
| Mereo Biopharma Group | 0.23% | Hold | 1,096,513 | $0.7069 | $775K | — | — |
| Surface Oncology | 0.23% | Add +40.5% | 1,100,000 | $0.6988 | $769K | +317,000 | +$127K |
| Karyopharm Therapeutics | 0.22% | Hold | 192,678 | $3.89 | $750K | — | — |
| Syros Pharmaceuticals | 0.21% | Hold | 265,878 | $2.67 | $710K | — | — |
| Spruce Biosciences | 0.21% | New | 312,000 | $2.21 | $690K | +312,000 | +$690K |
| ACRV - Acrivon Therapeutics | 0.19% | Add +226.9% | 51,148 | $12.69 | $649K | +35,500 | +$469K |
| Pardes Biosciences | 0.19% | Hold | 479,386 | $1.32 | $633K | — | — |
| Masimo | 0.17% | Hold | 3,000 | $184.54 | $554K | — | — |
| Kinnate Biopharma | 0.15% | Add +14.1% | 81,008 | $6.25 | $506K | +10,000 | +$73K |
| Regulus Therapeutics | 0.14% | Hold | 555,555 | $0.8475 | $471K | — | — |
| Medicenna Therapeutics | 0.12% | Hold | 660,000 | $0.6296 | $416K | — | — |
| Sutro Biopharma | 0.12% | New | 84,700 | $4.62 | $391K | +84,700 | +$391K |
| Ikena Oncology | 0.12% | Reduce −7.8% | 112,936 | $3.45 | $390K | −9,581 | +$64K |
| Adaptimmune Therapeutics | 0.11% | Hold | 351,064 | $1.09 | $383K | — | — |
| CMPX - Compass Therapeutics | 0.11% | Reduce −80.6% | 116,882 | $3.27 | $382K | −485,169 | −$3M |
| Nextcure | 0.08% | Hold | 187,696 | $1.48 | $278K | — | — |
| Holding | 0.06% | Hold | 140,000 | $1.50 | $210K | — | — |
| INGN - Inogen | 0.06% | Hold | 15,000 | $12.48 | $187K | — | — |
| Spero Therapeutics | 0.05% | Hold | 125,000 | $1.45 | $181K | — | — |
| Compugen | 0.04% | Hold | 205,202 | $0.7020 | $144K | — | — |
| Reunion Neuroscience | 0.00% | Reduce −73.6% | 12,598 | $0.6904 | $9K | −35,081 | −$34K |
Showing top 50 of 72 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| FATE - Fate Therapeutics | 1.57% | Exit | 0 | $10.09 | $6M | −550,940 | −$6M |
| 89BIO | 1.16% | Exit | 0 | $12.73 | $4M | −324,173 | −$4M |
| F-Star Therapeutics | 1.03% | Exit | 0 | $6.32 | $4M | −576,881 | −$4M |
| Cymabay Therapeutics | 0.30% | Exit | 0 | $6.27 | $1M | −171,059 | −$1M |
| Affimed | 0.24% | Exit | 0 | $1.24 | $851K | −686,282 | −$851K |
| Cincor Pharma | 0.17% | Exit | 0 | $12.29 | $590K | −48,000 | −$590K |
| BMEA - Biomea Fusion | 0.08% | Exit | 0 | $8.43 | $292K | −34,625 | −$292K |
| Macrogenics | 0.08% | Exit | 0 | $6.72 | $268K | −39,879 | −$268K |
| SCYXEUR - Scynexis | 0.07% | Exit | 0 | $1.56 | $239K | −153,269 | −$239K |
| BDTX — | 0.05% | Exit | 0 | $1.81 | $176K | −97,500 | −$176K |
| Phasebio Pharmaceuticals | — | Exit | 0 | $0.0311 | $10K | −321,856 | −$10K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2